Vitamin D supplementation, cancer incidence and mortality: Randomized trials revisited
In brief
Higher vitamin D levels link to 13% lower cancer mortality in deficient adults
In UK Biobank analyses modeled on two trials, higher vitamin D levels were associated with 13% lower cancer mortality among vitamin D-deficient adults; the association was smaller among those with insufficient levels. Trial-like analyses found no link in mostly vitamin D-replete populations, and these observational results do not show that supplements reduce cancer deaths.
- Journal
- European journal of cancer (Oxford, England : 1990) (Q1)
- Published
- 5 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Youqing Wang, Sha Sha, Tafirenyika Gwenzi, Ben Schöttker, Hermann Brenner
- PMID
- 43014140
- DOI
- 10.1016/j.ejca.2026.118142
Why clinicians should know about it
- Picked for Epidemiology (paper of the day, 13 November 2026): Examines observational confounding and trial generalizability for vitamin D
Abstract
BACKGROUND: Vitamin D insufficiency and deficiency are highly prevalent among older adults globally and have been associated with increased cancer mortality in observational studies. Large randomized trials (VITAL and D-Health) found no reductions in cancer incidence or mortality with vitamin D supplementation but included mostly vitamin D-sufficient populations. METHODS: Using UK Biobank (UKB) data, we conducted analyses informed by the VITAL and D-Health designs, applying their eligibility criteria and assuming the serum 25-hydroxyvitamin D (25(OH)D) increases observed in the trials (30 and 38 nmol/L, respectively). Populations meeting the trial criteria were weighted to match the trial baseline 25(OH)D distributions. To emulate alternative targeted interventions, analyses were restricted to vitamin D-insufficient or -deficient individuals (25(OH)D < 50 or < 30 nmol/L, respectively). Multivariable Cox models estimated associations per 30 or 38 nmol/L higher baseline 25(OH)D concentration over the corresponding trial follow-up periods. RESULTS: In analyses reflecting the original VITAL or D-Health 25(OH)D distributions, no association with cancer incidence or mortality was observed for the 25(OH)D increases achieved in the trials. However, inverse associations with cancer mortality were observed among vitamin D-insufficient and -deficient individuals, with hazard ratios (95% confidence intervals) of 0.93 (0.86-1.02) and 0.87 (0.77-0.97) in the VITAL-type cohort, and 0.92 (0.85-0.99) and 0.87 (0.80-0.96) in the D-Health-type cohort. CONCLUSION: Increases in 25(OH)D concentrations achieved in the trials were associated with substantially lower cancer mortality among vitamin D-insufficient and -deficient individuals. Null effects on cancer incidence and mortality observed in the trials were to be expected given the lack of associations between 25(OH)D and these outcomes among vitamin D replete populations.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.